Requires practitioners to discuss certain risks with a patient who is being prescribed a controlled substance or an opioid analgesic

The bill was amended to add three new sponsors (Senators Borrello, Harckham, and Rivera) and updated the committee status to reflect that the bill has been discharged from committee and reprinted. The core policy text regarding opioid prescribing requirements was modified to broaden the scope by removing the specific limitation to 'schedule II' controlled substances, thereby applying the discussion and referral requirements to all opioid drugs used for pain treatment.